Entering text into the input field will update the search result below

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

Nov. 12, 2021 8:36 PM ETAchilles Therapeutics plc (ACHL)
SA Transcripts profile picture
SA Transcripts

Achilles Therapeutics plc (NASDAQ:ACHL) SITC & Corporate Update Call November 12, 2021 8:30 AM ET

Company Participants

Lee Stern - VP, IR & External Communications

Iraj Ali - CEO

Karl Peggs - CMO

Sergio Quezada - CSO

Samra Turajlic - Chief Investigator, THETIS

Conference Call Participants

Joe Catanzaro - Piper Sandler

Tazeen Ahmad - Bank of America

Ingrid Gafanhao - Kempen

Lee Stern

We are glad you joined us for our review of today's SITC presentations and a brief corporate update. Prior to this call we issued a press release and posted a slide presentation that can be found on our website at www.achillestx.com. We will refer to this during our prepared remarks.

On today's call we have the pleasure of being joined by Dr. Samra Turajlic of the Royal Marsden's NHS Foundation Trust. Dr. Turajlic is the Chief Investigator of our THETIS clinical trial. In addition from Achilles, I am joined by Iraj Ali, our Chief Executive Officer; Karl Peggs, our Chief Medical Officer; and Sergio Quezada, our Chief Scientific Officer.

Before we start, I would like to remind everybody that today's statements will include forward-looking statements that are based on management's beliefs and assumptions and on currently available information.

Although we believe that the expectations reflected in these statements are reasonable, they relate to future events, future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.

The forward-looking statements on this call represent our views as of today, November 12, 2021, and we encourage you to review our SEC filings regarding specific risks and uncertainties.

With that I will turn the call over to Dr. Iraj Ali, CEO

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.